{'fraction_non_alphanumeric': 0.028169014084507043, 'fraction_numerical': 0.018227009113504555, 'mean_word_length': 5.425531914893617, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Serum enzyme tests in the diagnosis and follow-up of the evolution of sarcoidosis].

Due to the diagnosis difficulties posed by sarcoidosis, new metabolic or biological tests were suggested for replacing and/or confirming the histopathological examination: determination of the serous levels of the angiotensin-convertase (ACS), lysozyme and acid phosphatase. For establishing the ACS diagnosis value, the enzyme serous level was determined in 117 sarcoidosis patients, histopathologically confirmed (62 with active sarcoidosis, 55 with chronic sarcoidosis) in comparison with 109 patients suffering from other chronic lung affections. The results obtained, statistically processed, showed that the ACS level in active sarcoidosis is increased in 97% of the patients and only in 8% of the patients non-suffering from sarcoidosis. In active sarcoidosis, the ACS level has a positive predicting value of 86.8% and a negative one of 98%. The serous activities of lysozyme and acid phosphatase are not significant in sarcoidosis diagnosis. Of 59 treated patients with active sarcoidosis, in 58 the ACS value became normal after the clinical-radiological remission, thus showing the prognosis value of the test.